Back to Journals » OncoTargets and Therapy » Volume 11

Ultrasound-mediated microbubble destruction: a new method in cancer immunotherapy

Authors Tu J, Zhang H, Yu J, Liufu C, Chen Z

Received 13 April 2018

Accepted for publication 22 May 2018

Published 12 September 2018 Volume 2018:11 Pages 5763—5775

DOI https://doi.org/10.2147/OTT.S171019

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Federico Perche

Peer reviewer comments 3

Editor who approved publication: Dr Yao Dai


Jiawei Tu, Hui Zhang, Jinsui Yu, Chun Liufu, Zhiyi Chen

Department of Ultrasound Medicine, Laboratory of Ultrasound Molecular Imaging, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510150, People’s Republic of China

Abstract: Immunotherapy provides a new treatment option for cancer. However, it may be therapeutically insufficient if only using the self-immune system alone to attack the tumor without any aiding methods. To overcome this drawback and improve the efficiency of therapy, new treatment methods are emerging. In recent years, ultrasound-mediated microbubble destruction (UMMD) has shown great potential in cancer immunotherapy. Using the combination of ultrasound and targeted microbubbles, molecules such as antigens or genes encoding antigens can be efficiently and specifically delivered into the tumor tissue. This review focuses on the recent progress in the application of UMMD in cancer immunotherapy.

Keywords:
ultrasound, microbubble, cancer, immunotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]